Arm 2 Type of group

3 trials

Sponsors

AstraZeneca AB,, CureVac AG,, INSTITUTO NACIONAL DE ALERGIAS Y ENFERMEDADES INFECCIOSAS DE LOS ESTADOS UNIDOS,

Unknown Phase

ANTIPARASITIC THERAPY FOR NEUROCYSTICERCOSIS: PHASE II / III STUDY ON SAFETY AND EFFECTIVENESS AND COMBINED TREATMENT OF PRAZICUANTEL AND ALBENDAZOLE

Active, not recruitingPER-121-06

INSTITUTO NACIONAL DE ALERGIAS Y ENFERMEDADES INFECCIOSAS DE LOS ESTADOS UNIDOS,

Start: 2010-02-01Target: 180Updated: 2023-09-04

A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFICACY OF ADJUVANT DURVALUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN COMPLETELY RESECTED STAGE II-III NSCLC (MERMAID-1)

Active, not recruitingPER-043-20

AstraZeneca AB,

Start: 2020-12-15Target: 8Updated: 2023-11-13

RecruitingPER-106-20

Start: 2020-12-30Target: 10720Updated: 2023-11-13